 |
인쇄하기
취소
|
Hanmi signs deal to transfer entecavir synthesis technology to Hwail
Hanmi Pharmaceutical Co. signed Wednesday a license-out agreement with Hwail Pharmaceutical Co., a local pharmaceutical bulk maker, to transfer its new synthesis technology of entecavir.
Hanmi officials said that, under the agreement, Hwail will be able to produce entecavir until 2025 to meet the domestic demand using Hanmi’s patented technology.
“Entecavir requires a complicated synthesi...
Hanmi officials said that, under the agreement, Hwail will be able to produce entecavir until 2025 to meet the domestic demand using Hanmi’s patented technology.
“Entecavir requires a complicated synthesi...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.